The CD-19-targeted CAR T cells have been used as an important option to treat patients with certain incursive B-cell non-Hodgkin lymphomas (NHLs) and/or acute B-cell lymphoblastic leukemia (B-ALL) [130]. Here, CD19 is linked to B-cell acute lymphoblastic leukemia.